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AbstrACt
Objectives We identified factors associated with 
thromboembolic and bleeding events in two contemporary 
cohorts of anticoagulated patients with atrial fibrillation 
(AF), treated with either vitamin K antagonists (VKA) or 
non-VKA oral anticoagulants (NOACs).
Design Prospective, multicentre observational study.
setting 461 centres in seven European countries.
Participants 5310 patients receiving a VKA (PREvention 
oF thromboembolic events - European Registry in Atrial 
Fibrillation (PREFER in AF), derivation cohort) and 3156 
patients receiving a NOAC (PREFER in AF Prolongation, 
validation cohort) for stroke prevention in AF.
Outcome measures Risk factors for thromboembolic 
events (ischaemic stroke, systemic embolism) and 
major bleeding (gastrointestinal bleeding, intracerebral 
haemorrhage and other life-threatening bleeding).
results The mean age of patients enrolled in the PREFER 
in AF registry was 72±10 years, 40% were female and the 
mean CHA2DS2-VASc Score was 3.5±1.7. The incidence 
of thromboembolic and major bleeding events was 2.34% 
(95% CI 1.93% to 2.74%) and 2.84% (95% CI 2.41% to 
3.33%) after 1-year of follow-up, respectively. Abnormal 
liver function, prior stroke or transient ischaemic attack, 
labile international normalised ratio (INR), concomitant 
therapy with antiplatelet or non-steroidal anti-
inflammatory drugs, heart failure and older age (≥75 years) 
were independently associated with both thromboembolic 
and major bleeding events. With the exception of unstable 
INR values, these risk factors were validated in patients 
treated with NOACs (PREFER in AF Prolongation Study, 
72±9 years, 40% female, CHA2DS2-VASc 3.3±1.6). For 
each single point decrease on a modifiable bleeding risk 
scale we observed a 30% lower risk for major bleeding 
events (OR 0.70, 95% CI 0.64 to 0.76, p<0.01) and a 28% 
lower rate of thromboembolic events (OR 0.72, 95% CI 
0.66 to 0.82, p<0.01).
Conclusion Attending to modifiable risk factors is an 
important treatment target in anticoagulated AF patients 
to reduce thromboembolic and bleeding events. Initiation 
of anticoagulation in those at risk of stroke should not be 
prevented by elevated bleeding risk scores.
IntrODuCtIOn
Atrial fibrillation (AF) is a major risk factor 
for disabling stroke. Oral anticoagulation 
reduces the risk of stroke in patients with AF 
by almost two-thirds and is therefore recom-
mended for most patients with AF.1 2 
However, even on oral anticoagulation, 
stroke or systemic embolism occurs in 1%–4% 
of anticoagulated AF patients3–7 and approxi-
mately 2% experience a major bleed per year.8 
Reducing this burden of residual adverse 
events is desirable to improve outcomes.
To date, conditions predisposing to throm-
boembolic3 9–18 and bleeding events4 18–22 in 
anticoagulated AF patients have not been 
fully investigated. Their identification could 
strengths and limitations of this study
 ► We analysed a large and contemporary cohort of 
anticoagulated patients with atrial fibrillation (AF) 
enrolled across seven European countries.
 ► Our findings were validated in a second, indepen-
dent cohort of AF patients receiving a non-vitamin K 
antagonists oral anticoagulant for stroke prevention.
 ► These datasets were analysed in a retrospective 
fashion; thus our findings have to regarded as hy-
pothesis generating.
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help to improve outcomes in anticoagulated patients with 
AF. We therefore sought to identify factors associated 
with thromboembolic events and major bleeding in AF 
patients treated with either vitamin K antagonists (VKA) 
or non-VKA oral anticoagulants (NOACs).
MethODs
study population
We analysed outcomes in anticoagulated patients 
enrolled into the PREvention oF thromboembolic events 
- European Registry in Atrial Fibrillation (PREFER in 
AF) registry.21 Baseline data were obtained from consec-
utive AF patients in seven European countries (Austria, 
France, Germany, Italy, Spain, Switzerland and the UK) 
between January 2012 and January 2013. Patients were 
included if they were at least 18 years of age and had a 
history of AF documented by electrocardiography or by 
an implanted cardiac device within the preceding 12 
months.21
In order to reduce potential sources of bias and to 
achieve a cohort representative of the ‘real world’, no 
explicit exclusion criteria were defined. Investigators were 
encouraged to enrol patients consecutively to reduce 
selection bias.21 Patients receiving anticoagulation were 
included in the present analysis when information on 
outcome events was available during 1-year of follow-up.
We validated our findings in the independent PREFER 
in AF Prolongation cohort which contained 3156 AF 
patients treated with a NOAC, who were enrolled between 
June 2014 and May 2015.
This study was carried out in accordance with national 
law and the Declaration of Helsinki of 1975 (in its current 
revised form).
Outcome definitions
The combined ischaemic endpoint consisted of isch-
aemic stroke and systemic embolic events, including tran-
sient ischaemic attack (TIA), arterial embolism, venous 
thromboembolism or pulmonary thromboembolism.
The combined major bleeding endpoint included 
gastrointestinal bleeding requiring therapy, intracere-
bral haemorrhage and other life-threatening bleeding 
(resulting in substantial compromise requiring treat-
ment). Outcomes were reported and adjudicated by the 
respective investigators at each site.
statistical methods
Discrete characteristics are expressed as frequency 
counts and percentages. Continuous characteristics are 
expressed as means and SD or medians, where appro-
priate. Patients with missing data for outcome events or 
variables of interest were not included in the analysis.
Multivariable logistic regression with a stepwise inclu-
sion of covariates was used to identify predictors for 
thromboembolic events and major bleeding, including 
components of the validated HAS-BLED and CHA2DS2-
VASc risk stratification scheme and other variables 
available in the registry. For the best-performing clus-
ters of thromboembolic events and major bleeding risk 
factors, optimal integer coefficients were estimated using 
combinatorial testing of all integer weights via a logistic 
regression stepwise selection model. Cross validation was 
performed using bootstrapping (1000× random splitting 
of the cohort in two parts of identical in size). Predictors 
and integer coefficients in the first cohort were validated 
in the second cohort (which was not used for coefficient 
fitting). The most frequent predictors and for those the 
most frequent integer coefficients were presented as 
optimal integer coefficients.
The average over 1000 runs is presented as bootstrap-
ping area under the curve (AUC) together with variability 
estimation. Sensitivity analysis was performed by testing 
integer versus continuous coefficients, alternative age 
cut-offs, adequate rate control, rhythm control, presence 
of sinus rhythm, use of rhythm control therapy, presence 
of chronic kidney disease and different blood pressure 
cut-offs.
The receiver operating characteristic (ROC) contrast 
test was used to compare the predictive performance of 
the identified clusters of risk factors and established risk 
stratification schemes.23–26
The clusters of risk factors were independently vali-
dated in the PREFER in AF Prolongation Study, enrolling 
3156 anticoagulated AF patients between June 2014 and 
May 2015. Patients enrolled into both studies (PREFER in 
AF and PREFER in AF Prolongation) were excluded from 
the validation cohort. Labile international normalised 
ratio (INR) was defined as unstable INR values <60% time 
in therapeutic range, as adjudicated and reported by the 
respective investigators at each site.
SAS V. 9.4 was used for all statistical analysis.
Patient involvement
Patients were not involved in planning, design and 
conduct of the PREFER in AF study. Results were dissemi-
nated through press releases by the funding body and the 
primary results of the PREFER in AF study are available 
through open access publication.21
results
Patient characteristics
The PREFER in AF registry enrolled 7243 patients in 461 
European centres.
The clinical characteristics of the anticoagulated 
primary analysis population with available 1-year follow-up 
(5310 patients) are reported in table 1. All patients 
received oral anticoagulation, of whom 7.4% were treated 
with a NOAC (dabigatran 64%, rivaroxaban 34%, apix-
aban 2%).
At 1-year follow-up, there were 124 thromboembolic 
events, with a corresponding annual rate of 2.34% (95% 
CI 1.93% to 2.74%) (table 2).
In total, 151 (2.84%, 95% CI 2.41% to 3.33%) major 
bleeding events occurred in 145 patients. Of these, 74 
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(1.39%, 95% CI 1.10% to 1.75%) were gastrointestinal 
bleeding, 15 (0.28%, 95% CI 0.16% to 0.47%) were intra-
cerebral haemorrhages and 68 (1.28%, 95% CI 1.00% 
to 1.62%) were other life-threatening or major bleeding 
requiring therapy (six patients experienced more than 
one bleeding episode).
best-performing cluster of risk factors for thromboembolic 
events
On multivariable analysis a best-performing cluster of 
risk factors for thromboembolic events was identified. 
In descending order of relative risk, the inputs were 
abnormal liver function, prior stroke or TIA, labile INR, 
concomitant therapy with antiplatelet or non-steroidal 
anti-inflammatory drugs (NSAIDs), heart failure and 
age ≥75 years (table 3, figure 1).
Ninety-five per cent of patients with a labile INR 
received a VKA during the entire follow-up period, thus, 
the confounding effect of patients switched to a NOAC 
was insignificant.
Adequacy of rate control, the presence of sinus 
rhythm on follow-up, use of antiarrhythmic drugs, 
chronic kidney disease and alternative age cut-offs did 
not improve the score. Uncontrolled hypertension 
levels were low (only 3.3% of patients >160 mm Hg at 
1 year), diminishing a statistical impact on multivariable 
modelling.
The C-index with respect to the combined endpoint 
of thromboembolic events was 0.7402 (95% CI 0.6868 
to 0.7935, p<0.01 vs HAS-BLED) (online supplementary 
table 1).
Sensitivity analysis for a combined ischaemic endpoint 
excluding TIA, as well as for TIA only, show numerically 
consistent results (online supplementary tables 2 and 
3).
Table 1 Clinical characteristics of the study population
PREFER in AF study (derivation 
cohort, only anticoagulated 
patients)
n=5310
PREFER in AF Prolongation Study 
(validation cohort)
n=3156
Age 72.1±9.8 72.1±9.4
Gender (female) 39.5% 40.3%
BMI 28.1±5.0 28.1±4.9
SBP (mean) 131.7±16.5 134.2±16.2
DBP (mean) 77.6±10.2 78.7±10.0
CHADS2 score (mean/median, Q1, Q3) 2.0±1.3
2 (1; 3)
2.0±1.2
2 (1; 3)
CHA2DS2-VASc (mean/median, Q1, Q3) 3.5±1.7
3 (2; 5)
3.3±1.6
3 (2; 4)
CHA2DS2-VASc≥2 88.0% 88.6%
HAS-BLED score (mean/median, Q1, Q3) 2.0±1.1
2 (1; 3)
1.9±1.1
2 (1; 3)
HAS-BLED≥3 30.8% 26.1%
Congestive heart failure 31.0% 22.1%
Hypertension 73.1% 76.6%
Diabetes 23.7% 22.9%
Prior stroke/TIA 17.3% 15.7%
Vascular disease 23.4% 14.9%
Abnormal liver function 1.9% 0.9%
Abnormal renal function 13.7% 18.5%
Prior bleeding 4.8% 4.3%
Labile INR unstable/high INRs, <60% time in 
therapeutic range
15.3% 8.6%
Drugs (antiplatelet agents, NSAID) 20.1% 14.0%
Excess alcohol intake 2.5% 3.6%
BMI, body mass index; DBP, diastolic blood pressure; INR,  international normalised ratio; NSAID, non-steroidal anti-inflammatory 
drugs; PREFER in AF, PREvention oF thromboembolic events - European Registry in Atrial Fibrillation; SBP, systolic blood pressure; TIA,  
transient ischaemic  attack.
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best-performing cluster of major bleeding risk factors
The best-performing cluster of major bleeding risk 
factors included modifiable inputs of the HAS-BLED 
score (except for hypertension, due to low exposure to 
elevated blood pressure levels), a modified age cut-off 
and vascular disease (table 4, figure 2). The C-index for 
major bleeding was 0.6982 (95% CI 0.6529 to 0.7469, 
p<0.01 vs HAS-BLED) (online supplementary table 1).
For each single point decrease in this cluster of mostly 
modifiable bleeding risk factors we observed a 30% lower 
relative risk for major bleeding events (OR 0.70, 95% CI 
0.64 to 0.76, p<0.01). When applied to evaluate the risk for 
thromboembolic events, there was a 28% lower event rate 
per point decrease on this adjusted modifiable bleeding 
risk scale (OR 0.72, 95% CI 0.66 to 0.82, p<0.01).
Based on this observation, for each single point decrease 
on this best-performing scale of modifiable bleeding risk 
factors, we estimate a number needed to treat (NNT) 
of 111 to prevent one major bleeding event (0.9% abso-
lute risk reduction) and an NNT of 143 to prevent one 
ischaemic event (0.7% absolute risk reduction) during 
1-year of treatment.
Validation in the PreFer Prolongation study
The identified clusters for thromboembolic and major 
bleeding events were independently validated in the 
PREFER Prolongation Study, which enrolled 3156 AF 
patients receiving a NOAC for stroke prevention. Rivarox-
aban was used in 50%, apixaban in 26% and dabigatran 
in 24% of patients. Clinical characteristics were similar to 
the derivation cohort in terms of age (72±9 years), gender 
(40% female), stroke risk (CHA2DS2-VASc 3.3±1.6) and 
bleeding risk (HAS-BLED 1.9±1.1) (table 1).
Labile INR was reported in 6.9% of patients in the vali-
dation cohort and validation was performed disregarding 
labile INR, as well as accounting for labile INR as a surro-
gate for poor compliance.
The clusters of risk factors for thromboembolic events 
and major bleeding had numerically higher c-indices 
than established risk scores for the respective outcomes, 
Table 2 Incidence of thromboembolic events in the PREvention oF thromboembolic events - European Registry in Atrial 
Fibrillation (PREFER in AF) study (derivation cohort) and the PREFER in AF Prolongation Study (validation cohort)
Events (count) Annual event rates (95% CIs)
PREFER in AF (derivation cohort)
  Stroke or SEE 124 2.34% (1.93% to 2.74%)
   Ischaemic stroke 43 0.81% (0.59% to 1.09%)
   TIA 64 1.21% (0.93% to 1.54%)
   Embolic events* 27 0.51% (0.34% to 0.74%)
PREFER in AF Prolongation (validation cohort)
  Stroke or SEE 53 1.68% (1.26% to 2.19%)
   Ischaemic stroke 24 0.76% (0.49% to 1.13%)
   TIA 27 0.86% (0.56% to 1.24%)
   Embolic events* 6 0.19% (0.07% to 0.41%)
*Including arterial embolism, venous thromboembolism or pulmonary thromboembolism.
SEE, systemic embolic event; TIA, transient ischaemic attack.
Table 3 Risk factors associated with thromboembolic events (PREvention oF thromboembolic events - European Registry in 
Atrial Fibrillation derivation cohort)
Variable OR 95% CI P value Score
Abnormal liver function* 2.86 1.24 to 6.63 0.0141 2
Labile INR† 2.83 1.83 to 4.38 <0.0001 2
Drugs‡ 2.41 1.58 to 3.69 <0.0001 1
Prior stroke/TIA/thromboembolic event 2.79 1.81 to 4.28 <0.0001 2
Heart failure 2.20 1.45 to 3.33 0.0002 1
Age ≥75 years 1.53 1.00 to 2.33 0.0482 1
*Presence of cirrhosis, elevated liver transaminases or alkaline phosphatase >3 times above the upper limit of normal (ULN), or bilirubin >2 
times above the ULN.
†<60% time in therapeutic range.
‡Antiplatelet agents or non-steroidal anti-inflammatory drugs.
INR, international normalised ratio; TIA, transient ischaemic attack.
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consistent with results from the derivation cohort (online 
supplementary table 4). Lower absolute c-indices and 
non-significant differences regarding the predictive 
performance between the scores are reflected by a lower 
sample size and a lower incidence of outcome events in 
the validation cohort.
Validation results were consistent when labile INR was 
accounted for as a surrogate for poor compliance (online 
supplementary table 5).
DIsCussIOn
The main finding of this study is that in a large cohort of 
anticoagulated AF patients, modifiable risk factors can be 
attributed to a substantial proportion of both thrombo-
embolic and major bleeding events. In addition, this anal-
ysis confirmed other risk factors for embolic and bleeding 
events in anticoagulated AF patients such as prior stroke, 
older age and heart failure. Major modifiable factors were 
Figure 1 Risk factors for thromboembolic events in anticoagulated atrial fibrillation patients, presented as ORs with 95% CIs 
(PREvention oF thromboembolic events - European Registry in Atrial Fibrillation derivation cohort). *Concomitant therapy with 
antiplatelet agents or non-steroidal anti-inflammatory drugs. INR, international normalised ratio; TIA, transient ischaemic attack. 
Table 4 Risk factors associated with major bleeding (PREvention oF thromboembolic events - European Registry in Atrial 
Fibrillation derivation cohort)
Variable OR* 95% CI P value OR† 95% CI P value Score
Bleeding predisposition‡ 4.10 2.54 to 6.60 <0.0001 3.87 2.32 to 6.47 <0.0001 4
Age ≥75 years 2.16 1.52 to 3.07 <0.0001 1.99 1.36 to 2.91 0.0004 2
Vascular disease§ 1.92 1.35 to 2.73 0.0003 1.65 1.11 to 2.43 0.0125 1
Abnormal renal function¶ 1.78 1.18 to 2.69 0.0062 1.50 1.01 to 2.23 0.0401 1
Abnormal liver function¶ 3.48 1.65 to 7.35 0.0011 3.24 1.47 to 7.15 0.0035 2
Labile INR** 1.44 1.00 to 2.08 0.0492 1.31 0.91 to 1.89 0.0965 1
Excess alcohol 1.85 1.07 to 3.20 0.0134 1.94 1.02 to 3.69 0.0472 2
Drugs†† 1.78 1.23 to 2.58 0.0023 1.35 0.89 to 2.05 0.1581 1
*Univariate analysis.
†Multivariable analysis.
‡History of bleeding/anaemia (HAS-BLED).
§Peripheral artery disease, prior myocardial infarction, aortic plaque (CHA2DS2-VASc).
¶Abnormal renal function (HAS-BLED): serum creatinine >2.3 mg/dL (200 μmol/L), renal transplantation or chronic dialysis. Abnormal liver function (HAS-BLED): 
cirrhosis, elevated liver transaminases or alkaline phosphatase >3 times above the upper limit of normal (ULN), or bilirubin >2 times above the ULN.
 **<60% time in therapeutic range.
††Antiplatelet agents or non-steroidal anti-inflammatory drugs.
INR, international normalised ratio.
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labile INR values (in patients treated with VKA), concom-
itant therapy with antiplatelet agents or NSAIDs and as a 
potentially modifiable risk factor liver damage.
The modifiable risk factors identified here overlap 
with modifiable bleeding risk factors highlighted in the 
2016 European Society of Cardiology (ESC) AF guide-
lines (uncontrolled hypertension, labile INR, antiplatelet 
drugs or NSAIDs and excess alcohol intake).1 Our esti-
mates suggest that patients in whom modifiable bleeding 
risk factors are minimised as part of an integrated 
management approach for AF might also be at lower risk 
for thromboembolic events.9–17 Also in line with previous 
data, our analysis demonstrates that the CHA2DS2-VASc 
score was inferior in terms of bleeding risk prediction 
compared with the HAS-BLED score and should not 
be used to estimate bleeding risk in anticoagulated AF 
patients.19 20 27
Simple measures that could be helpful to reduce 
residual thromboembolic and major bleeding events in 
anticoagulated patients suggested by our analysis include:
1. Switching from a VKA to a NOAC in patients with la-
bile INR values.
2. Timely discontinuation of antiplatelet therapy and mi-
nimisation of treatment with NSAIDs.
As shown previously, patients with well controlled INR 
values have a significantly lower risk for adverse cardio-
vascular outcomes. Adding time in therapeutic range to 
established bleeding risk stratification schemes such as 
the ATRIA and ORBIT score significantly improved their 
predictive performance.28–30 This further underlines the 
importance of a high-quality anticoagulation control in 
case VKA are used and the need for adequate adherence 
to NOACs.31
Blood pressure was well controlled in our cohorts, thus 
limiting our ability to quantify the impact of uncontrolled 
hypertension on thromboembolic events and major 
bleeding.1 32
Successful treatment of chronic kidney or liver disease 
may contribute to improve outcomes.1 33 Liver disease 
may also be a proxy for alcohol abuse, a factor that has 
been associated with bleeding in other cohorts.34
Our results also support the concept that the initiation 
or withdrawal of anticoagulation should not be based on 
bleeding risk, as stroke risk and bleeding risk are intri-
cately linked. Instead, the increasing returns in terms 
of net clinical benefit—by treating subjects with greater 
thromboembolic risk—should be considered when initi-
ating oral anticoagulation in AF patients.4 35 36 Impor-
tantly, we have been able to validate our findings in a 
cohort of AF patients anticoagulated with NOACs.
lIMItAtIOns AnD strengths
The management of patients in included in the PREFER 
in AF registry is well aligned with evidence-based therapy 
and current treatment guidelines, underlining the gener-
alisability of our findings in contemporary clinical prac-
tice. Worth mentioning, the derivation and validation 
cohort were recruited consecutively, thus in different 
periods in time (January 2012–January 2013 and June 
2014–May 2015). We cannot fully explain the association 
of the risk factors identified in this analysis with both 
Figure 2 Risk factors for major bleeding events in anticoagulated atrial fibrillation patients, presented as ORs with 95% CIs 
(PREvention oF thromboembolic events - European Registry in Atrial Fibrillation derivation cohort). *Concomitant therapy with 
antiplatelet agents or non-steroidal anti-inflammatory drugs. INR, international normalised ratio.
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major bleeding and thromboembolism. Importantly, our 
findings are based on associations and hence hypothe-
sis-generating. While we were able to validate our findings 
in an independent cohort, interventional trials testing 
the simple interventions identified in our analysis are 
desirable to assess their effect on thromboembolic and 
major bleeding outcomes.
While it seems intuitive that labile INR values predispose 
to both bleeding and stroke, it is less clear how concom-
itant therapy with antiplatelet agents or NSAIDs can 
contribute to stroke risk. It is conceivable that bleeding 
events led to temporary disruption of anticoagulation, 
thereby increasing the risk for thromboembolic events. 
In addition, concomitant therapy with these substances 
could be a marker for patients at higher risk of ischaemic 
events due to confounders that were not captured in our 
data set.
COnClusIOn
A substantial number of thromboembolic and major 
bleeding events in anticoagulated patients with AF can be 
attributed to a few modifiable risk factors. For each single 
point decrease on an adjusted modifiable bleeding risk 
scale, we observed an approximately 30% reduction in 
both major bleeding and thromboembolic events.
Our findings suggest that normalising INR, avoiding 
exposure to antiplatelet agents or NSAIDs and preventing 
liver disease could reduce both bleeding and residual 
stroke risk in AF patients receiving anticoagulation.
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